🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The Johns Hopkins Department of Psychiatry is conducting a research study t...
Status
Completed
Location
Johns Hopkins
Start Date
2004-05
Trial ID
NCT00376220
This study examines if Riluzole, FDA approved for ALS, will improve symptom...
Status
Terminated
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Start Date
2003-02
Trial ID
NCT00054704
RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be a...
Status
Terminated
Location
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Start Date
2007-02
Trial ID
NCT00667901
The objective is to compare the efficacy and safety of masitinib in combina...
Status
Not Yet Recruiting
Location
Aiginition Hospital
Start Date
2026-01-01
Trial ID
NCT07174492
Treatments Being Tested
The objective of the study is to compare the pharmacokinetic profile of ril...
Status
Completed
Location
CROSS Research SA Phase 1 Unit
Start Date
2021-01-15
Trial ID
NCT04819438
Treatments Being Tested
The hereditary cerebellar ataxias include diverse neurodegenerative disorde...
Status
Completed
Location
Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, II Faculty of Medicine, "Sapienza" University of Rome
Start Date
2010-04
Trial ID
NCT01104649
Treatments Being Tested
MIROCALS is a phase II study of ld-IL-2 as a therapeutic agent for ALS. A r...
Status
Completed
Location
CHRU de Lille - Hôpital Roger Salengro
Start Date
2017-06-19
Trial ID
NCT03039673
Treatments Being Tested
The goal of the current proposal is to examine if sublingual riluzole can r...
Status
Completed
Location
Connecticut Mental Health Center
Start Date
2017-01
Trial ID
NCT03017508
Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inher...
Status
Recruiting
Location
Neurological Unit, S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome
Start Date
2021-06-01
Trial ID
NCT03660917
Y-4 is a new fixed-dose combination drug product containing two active ingr...
Status
Recruiting
Location
Beijing Tiantan Hospital, Capital Medical University Beijing
Start Date
2025-05-19
Trial ID
NCT07013773
Treatments Being Tested